Graham Capital Management’s Soleno Therapeutics SLNO Stock Holding History

Graham Capital Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,507	Closed	-$352K	–	1486
2026 Q1	$352K	Buy	10,507 +3,877	+58%	+$152K	0.01%	754
2025 Q4	$307K	Sell	6,630 -9,744	-60%	-$534K	0.01%	842
2025 Q3	$1.11M	Buy	+16,374	New	+$1.21M	0.02%	355

Graham Capital Management's SLNO Position: Q2 2026 in Review

Graham Capital Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 10,507 shares — an estimated $352K sold.

Graham Capital Management first reported a position in SLNO in Q3 2025 and held it in 3 quarters. The position peaked at $1.11M in Q3 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Graham Capital Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Graham Capital Management sold 10,507 Soleno Therapeutics shares in Q2 2026, an estimated $352K.
Graham Capital Management first reported a position in Soleno Therapeutics in Q3 2025 and held it in 3 quarters.
Graham Capital Management's Soleno Therapeutics position peaked at $1.11M in Q3 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.